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11. IN VIVO STUDIES¶
Lysostaphin is a potent enzymatic anti-staphylococcal agent that lyses the
cell walls of staphylococci in vitro. Studies described in the preceding
paper demonstrated that lysostaphin rapidly killed staphylococci, was un-
affected by human serum, and maintained its activity after prolonged incu-
bation at body temperature.' Unlike the penicillins, lysostaphin was active
in vitro against very large populations of stationary phase staphylococci.
Serious staphylococcal infections continue to pose major therapeutic
problems despite the introduction of the penicillinase-resistant penicillins
and cephalosporins. Mortality rates from staphylococcal bacteremia ap-
proach 30%o,' and may be higher in staphylococcal endocarditis, especially
when prosthetic cardiac valves are infected. It is believed that the thera-
peutic failures often result from the relative impotence of currently avail-
able antimicrobials against staphylococci residing in high titers in abscess
lesions. Thus the availability of a chemotherapeutic agent active against
large numbers of staphylococci in such lesions might be of great im-
portance. Lysostaphin was therefore further studied as a therapeutic agent
in experimental staphylococcal infections. These studies show that lysos-
taphin is highly effective in the treatment of experimental staphylococcal
disease.
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METHODS
Two coagulase-positive strains of Staphylococcus aureus were utilized in these
studies. The Giorgio strain (previously described'8) is inhibited by 0.39 ug/ml. of
oxacillin. The Diffuse variant of the Smith strain has also been extensively char-
acterized."' It is coagulase positive, clumping factor negative, possesses an anti-
phagocytic surface antigen, and is virulent for mice when injected intraperitoneally.
It is inhibited by 25 ,ug/ml. of penicillin G. Cultures were maintained on trypticase
soy agar slants at 40 C. Eighteen-hour transplants in trypticase soy broth were used
in all experiments.
In one group of experiments 20 g Swiss albino mice* were infected by intra-
peritoneal injections of 0.4 ml. of the Diffuse culture containing approximately 5 x 108
viable staphylococcal units. Animals were sacrificed at intervals for quantitative
bacterial counts, as described previously.' One milliliter of sterile saline was used to
wash the peritoneal cavity and was then diluted appropriately and plated in trypticase
soy agar. Additional groups of infected mice were observed for 24 hours to determine
mortality rates.
In another group of experiments, mice were infected via a tail vein with 0.2 ml.
(approximately 2 x 108 viable staphylococcal units) of the Giorgio strain. Animals
were sacrificed at intervals and kidneys removed aseptically. Each pair of kidneys
was placed in 4 ml. of sterile 0.9% saline in a graduated centrifuge tube so that the
fluid displaced indicated kidney volume. Specimens for staphylococcal L-form isolation
were placed in 5% saline. The kidneys were then homogenized in the saline using
a Teflon tissue grinder. Homogenates were diluted appropriately and plated in trypti-
case soy agar. Culturable units of staphylococci per milliliter of kidneys were calcu-
lated from kidney volumes. Additional groups of infected mice were observed for
28 days to determine cumulative mortality rates.
Crude alpha hemolysin was prepared from the Diffuse colonial variant of the Smith
strain growth for six days in modified Burnet's broth into which 20%o C02 was
bubbled continuously.' Culture supernatants were Millipore filtered and assayed for
hemolytic activity (hemolytic titer 1: 64).
Media for the recovery of L-forms was prepared according to the method of
Kagan,' and contained 6 g. of brain heart infusion agar, 6.7 g. of NaCl, 116 ml. of
distilled water, and 30 ml. of sterile pooled human plasma, which had been inactivated
at 56' C., frozen overnight at -20' C. and Zeitz filtered. Aliquots of kidney
homogenates in 5% saline were streaked on the surface of agar plates and incubated
at 37' C. for at least five days. Daily observations of the plates were performed
using a binocular dissecting microscope. L-forms appeared as tiny "fried-egg" colonies
which grew into the agar and could not be moved easily with a bacteriological loop.
Serial transfers were made by cutting out agar blocks and streaking them on fresh
plates.
A modification of the Ouchterlony agar gel diffusion technique was employed to
demonstrate precipitin antibody.8 The media contained 1.2% agar in 0.85% NaCl and
1: 10,000 merthiolate. Wells were placed X inch apart in agar plates. Plates were
incubated overnight at 37' C., the wells filled with appropriate solutions, and the plates
reincubated at 37' C. for 18 hours. An additional day at room temperature or at
4' C. allowed maximum production of precipitin bands.
*Dublin Laboratory Animals, Inc., Dublin, Virginia.
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Neutralizing antibody was measured using 50% serum from mice or rabbits*
immunized with lysostaphin.t The standard assay for enzyme activity was performed
as previously described.'
Chi square tests were used in evaluating the statistical significance of differences in
mortality rates. In assessing the significances of differences in the averages of log titer
determinations, t tests were used except in certain cases where rank sum tests seemed
to be indicated because of variance heterogeneity in the data. Two-tailed tests were
used in all cases.
TABLE 1. THE EFFECT OF LYSOSTAPHIN AND PENICILLIN G ON THE
INTRAPERITONEAL MOUSE INFECTION WITH THE SMITH DIFFUSE
STAPHYLOCOCCUS. TREATMENT AT 4 HouRs
Per cent
Survivors/total surviving
Control 2/33 6
Penicillin G 9/17 53
2.5 mg. IV
Lysostaphin 34/34 100
2.5 mg. IV
RESULTS
Efficacy of lysostaphin in an intraperitoneal staphylococcal infection in
mice
Intraperitoneal infection with the diffuse colonial variant of the Smith
strain of Staphylococcus aureus produces almost 100% mortality within
6 to 10 hours.4'5 Staphylococcal alpha hemolysin produced by rapidly
multiplying microorganisms is the cause of death."'9 In the present study
mice were treated intravenously with a single 2.5 mg. dose of either lysos-
taphin or penicillin G four hours after intraperitoneal infection. Mice
succumbing to the infection all died within 12 hours. Survivors were
observed for 72 hours after challenge. Such an experiment is shown in
Table 1. Only 6% of control animals survived. While 53%o of the mice
treated with penicillin survived, all the mice treated with lysostaphin lived.
This is a significant difference in survival (.01 > p > .001). Cultures
of intraperitoneal contents obtained six hours after infection showed no
differences between intraperitoneal staphylococcal titers of control and
* Male albino rabbits (2.5 to 3 kg.) from H and M Rabbits Breeders, Louisville,
Kentucky.
t Lot no. 142-123-1 kindly supplied by Dr. Peter Tavormina of the Mead Johnson
Research Center, Evansville, Indiana.
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penicillin-treated mice (Table 2). Lysostaphin significantly reduced the
intraperitoneal staphylococcal titers when compared with the results in
the penicillin-treated animals (p > .01). Staphylococci isolated from the
peritoneal cavities of lysostaphin-treated mice were uniformly sensitive to
lysostaphin.
TABLE 2. INTRAPERITONEAL INFECTION IN MICE WITH THE SMITH DIFFUSE
STAPHYLOCOCCUS. TREATMENT AT 4 HOURS AND AT 6 HOURS
(Intraperitoneal titers)
4 hours 6 hours
Onset of infection after infection after infection
Control 4.1 x 108 1.1 x 108 1.7 x 10'
3.3 x 108 1.1 x 109 1.4x 109
2.9 x 10' 1.0 x 109 5.7 x108
Penicillin G 2.1 x 108
2.5 mg. IV 9.5 x 10"
3.1 x 107
Lysostaphin 2.7 x 108
2.5 mg. IV 3.6 x 10'
3.2 x 108
TABLE 3. LYSOSTAPHIN-STAPHYLOCOCCAL ALPHA HEMOLYSIN INTERACTION
Mortality of mice
at 24 hours
Control 0.5 ml. of alpha hemolysin IP 7/8
Lysostaphin 0.5 ml. of alpha hemolysin IP; 7/10
treatment 30 minutes later treated with
lysostaphin, 2.5 mg. IV
Lysostaphin- 0.5 ml. of alpha hemolysin + 5/5
alpha hemolysin 2.5 mg. lysostaphin incubated
mixture at 37° C. for 30 minutes,
then injected IP
Because death in this infection results from staphylococcal alpha hemo-
lysin production, two studies were performed to determine whether lysos-
taphin interfered with the biological activity of alpha hemolysin. As shown
in Table 3, 0.5 ml. of crude alpha hemolysin was lethal for mice.
Lysostaphin administered 30 minutes after intraperitoneal injection of
crude alpha hemolysin did not increase the survival of mice. Preincuba-
tion of lysostaphin with alpha hemolysin did not alter its mouse-lethal
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properties. Hence, the survival of infected mice treated with lysostaphin
appeared to represent a direct effect on the staphylococcal cell.
Efficacy of lysostaphin in an intravenous staphylococcal infection in mice
When injected intravenously into mice,"'0 the Giorgio strain of Staphy-
lococcus aureus produces a progressive and usually fatal staphylococcal
pyelonephritis with abscess formation. The Giorgio strain is sensitive
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FIG. 1. Intravenous infection of mice with the Giorgio staphyloccus. Survival rates
after intravenous treatment at 6 hours after infection with 2.5 mg. of either lysostaphin
or oxacillin. The numbers in parentheses indicate the number of mice in each group.
to oxacillin (M.I.C. 0.39 ,ug/ml.). In these studies mice were treated
6 or 24 hours after intravenous infection with a single intravenous dose
of 2.5 mg. of either lysostaphin or oxacillin (approximately 100 mg/kg.).
As shown in Figure 1, only 10% of untreated control mice were alive
four weeks after infection. When the single intravenous treatment was
given 6 hours after infection, oxacillin increased the survival rate of
27%o. This was a significant increase in survival rate (p > .01). How-
ever, all of the mice treated with lysostaphin survived. The difference
between the survival rates of the oxacillin and lysostaphin-treated animals
was highly significant (p > .001).
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When such single dose treatment was delayed until 24 hours after in-
fection, the survival rates shown in Figure 2 were obtained. Treatment with
oxacillin yielded a 30%o survival rate, significantly greater than that
among untreated mice (p > .01). Lysostaphin treatment protected 56%o
of the animals, a result significantly better than that observed with
oxacillin (p > .01).
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FIG. 2. Intravenous infection of mice with the Giorgio staphylococcus. Survival rates
after intravenous treatment at24 hoursafter infection with 2.5 mg. of either lysostaphin
or oxacillin. The numbers in parentheses indicate the number of mice in each group.
Maximum staphylococcal multiplication occurs in the kidneys when mice
are infected intravenously.'0 The concentrations of microorganisms in the
kidneys were thus determined to define more precisely the effects of
therapy. As shown in Figure 3, kidneys contained approximately 105 to
106 staphylococci per milliliter 6 hours after infection. The staphylococcal
populations in the kidneys of untreated mice gradually increased over
the 7-day period studied, reaching a maximum titer of more than 109
microorganisms/ml. A single dose of oxacillin 6 hours after infection did
not significantly alter kidney microbial populations. Lysostaphin, as com-
pared with oxacillin, significantly reduced the concentration of staphylo-
cocci in the kidneys, 1 day, 3 days, and 7 days after infection. In some
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kidneys of lysostaphin-treated mice, no culturable staphylococci could be
demonstrated.
If treatment were delayed until 24 hours after infection (Fig. 4), kidneys
from untreated mice contained between 106 and 108 staphylococci/ml. A
single dose of oxacillin did not significantly alter these populations. In
contrast, lysostaphin significantly lowered the bacterial titers when com-
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FIG. 3. Intravenous infection of mice with the Giorgio staphylococcus. Kidney titers
after intravenous treatment at 6 hours after infection with 2.5 mg. of either lyso-
staphin or oxacillin. The lines connect the means in each group.
pared with oxacillin 3 days and 7 days after infection. Staphylococci
isolated from the kidneys of mice treated with lysostaphin all retained
their sensitivity to the enzyme.
Another therapeutic program was then devised to approximate more
closely the conditions of clinical practice. In this instance both single
and multiple dose oxacillin regimens were compared with a single injection
of lysostaphin. Six hours after intravenous infection with the Giorgio
staphylococcus, mice were treated intravenously with 2.5 mg. of either
lysostaphin or oxacillin. One group of oxacillin-treated mice then receivred
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additional oxacillin, 2.5 mg. intramuscularly, for each of the next four
days. The lysostaphin-treated mice received no further treatment. As
shown in Figure 5, while the multiple-dose oxacillin regimen improved
survival rates, a single lysostaphin treatment resulted in a 90%o survival
rate, significantly higher than either oxacillin treatment program (p >
.001).
CONTROL OXACILLIN LYSOSTAPHIN
* 1 .50 109 * S
0
l.o's * S 0
w ~~~~~~~0
z
107i ' '
0s log4
aL.
13 4
0
U
t
0
10~~~~~~~~~~~~~~~~
I 3 ~7 1 3 7 1 7
DAYS
FIG. 4. Intravenous infection of mice with the Giorgio staphylococcus. Kidney titers
after intravenous treatment at 24 hours after infection with 2.5 mg. of either lyso-
staphin or oxacillin. The lines connect the means in each group.
Five days after intravenous infection with the Giorgio staphylococcus
most mice have gross renal cortical abscesses (Fig. 6). To determine the
effect of lysostaphin and oxacillin on such staphylococcal populations, mice
were treated once intravenously with 5 mg. of either lysostaphin or
oxacillin (approximately 200 mg/kg.) on the 5th day after infection. After
24 hours, kidney staphylococcal titers were determined. All kidneys had
grossly visible cortical abscesses. As shown in Figure 7, kidneys from
untreated mice contained greater than 109 microorganisms/ml. The kid-
neys from the oxacillin-treated group contained similar microbial popula-
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FIG. 5. Intravenous infection of mice with the Giorgio staphylococcus. Survival rates
after treatment at 6 hours after infection with single doses of lysostaphin or oxacillin
or multiple doses of oxacillin. The numbers in parentheses indicate the number of mice
in each group.
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FIG. 7. Intravenous infection of mice with the Giorgio staphylococcus. Kidney
staphylococcal titers after treatment of established renal abscesses. Five milligrams of
either lysostaphin or oxacillin were given intravenously 5 days after infection.
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Volume 39, February, 1967FIG. 6. The appearance of renal abscesses in mice infected with the Giorgio
staphylococcus 5 days previously.
FIG. 8. Colonies of staphylococcal L-forms on solid media. The large shadow on
the left is a portion of the parent staphylococcal colony. X 50.
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FIG. 10. Agar diffusion plate. Center well contains lysostaphin. Well 1 contains
serum from mice immunized with multiple doses of lysostaphin in Freund's adjuvant.
Well 2 contains serum from mice immunized with multiple doses of intravenous
lysostaphin. Wells 3 and 4 contain serum from rabbits obtained 4 days after the
4th intravenous dose of lysostaphin.Lysostaphin, in vivo studies SCHAFFNER, MELLY, KOENIG
tions. In contrast, lysostaphin had significantly reduced the staphylococcal
population of the abscessed kidneys (p > .01). Thus, lysostaphin was
active against high titers of staphylococci inside the abscess lesion.
Production of staphylococcal L-forms by lysostaphin
It has been suggested that the persistence of staphylococcal infection
and the relapses of staphylococcal disease after conventional antimicrobial
therapy are due to the formation of staphylococcal L-forms in tissues.'
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FIG. 9. Effect of 50% lysostaphin-immune rabbit serum on in vitro lysostaphin
activity (70,ug/ml.): (1) Lysostaphin activity in normal rabbit serum. (2) Lyso-
staphin activity in serum obtained 14 days after a single intravenous injection of
lysostaphin. (3) Lysostaphin activity in serum obtained 4 days after two intravenous
injections of lysostaphin separated by 3 days. (4) Lysostaphin activity in serum
obtained 4 days after the 4th intravenous injection of lysostaphin administered over
3 to 4-day intervals.
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As lysostaphin lyses staphylococcal cell walls while, presumably, leaving
cell membrane and bacterial cytoplasm intact, the in vitro and in vivo
production of L-forms by lysostaphin was investigated.
Lysostaphin readily produced staphylococcal L-forms in vitro. After their
production in hypertonic salt broth they grew as typical "fried-egg"
colonies on agar containing salt and human serum (Fig. 8). These osmo-
tically fragile L-forms could be maintained through several passages on
solid media not containing lysostaphin or other antibiotics. Eventually they
slowly reverted to the usual bacterial forms that had the same charac-
teristics and phage type as the parent strain.
Attempts were then made to isolate L-forms from the kidneys of mice
infected intravenously with the Giorgio staphylococcus and treated with
lysostaphin or oxacillin. When mice were treated intravenously 6 hours
after infection with 2.5 mg. of either lysostaphin or oxacillin, staphylo-
coccal L-forms were isolated from their kidneys from /2 to 2 hours
after treatment with either drug, while no L-forms could be isolated
from kidneys of untreated control animals. As with the L-forms produced
in vitro, these microorganisms reverted to typical staphylococci that ap-
peared identical to the parent strain and possessed the same phage type.
However, L-forms could not be cultured from any kidneys at 24 and 48
hours after treatment and at the four week termination of the experiment.
Observations on theimmunology of lysostaphin
Lysostaphin is a protein with a molecular weight of approximately
30,000. Its antigenicity and the nature of the antibody produced in response
to its parenteral administration in mice and rabbits were therefore studied.
Rabbits were immunized with single or multiple intravenous injections
of 40 mg. of lysostaphin (approximately 13 mg/kg.). The multiple doses
were spaced at intervals of 3 or 4 days for four doses, then every two
weeks for two additional doses. There were no discernable adverse re-
actions to this repeated intravenous administration of the enzyme. As
shown in Figure 9, serum obtained 14 days after the intravenous adminis-
tration of a single dose of lysostaphin or 4 days after two intravenous
doses did not interfere with in vitro lysostaphin activity. However, serum
obtained 4 days after the fourth dose of the multiple-dose regimen did
significantly interfere with the lytic activity of lysostaphin. When lysos-
taphin was added to this serum, a visible precipitate was observed and
agar diffusion techniques demonstrated a single broad precipitin line
(Fig. 10). Rabbits in which such precipitating and neutralizing antibody
was demonstrated received two further intravenous injections of lysostaphin
without observed ill effects.
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Immunological studies in mice are summarized in Table 4. Mice were
immunized at 3 day intervals with four intramuscular doses of 2.5 mg.
of lysostaphin emulsified with incomplete Freund's adjuvant. Eleven days
after the last immunization 10 mice were challenged with 2.5 mg. of
lysostaphin intravenously. All 10 died a respiratory death within 30 to
40 minutes. Precipitating antibody could not be demonstrated in serum
from such mice using agar diffusion techniques (Fig. 10).
Mice were also immunized intravenously with lysostaphin alone. Two
schedules were employed. One group of animals received four doses of
TABLE 4. IMMUNOLOGICAL STUDIES IN MICE
Mortality
Immunization schedule (killed/total)
1. Lysostaphin in incomplete Freund's adjuvant
Immunized IM Q3 days for 4 doses 10/10
Challenged IV 11 days after last dose
2. Lysostaphin
Immunized IV Q3 days for 4 doses 1/10
Challenged IV 12 days after last dose
3. Lysostaphin
Immunized IV every day for 5 days 1/10
Challenged IV 12 days after last dose
4. Equine tetanus antitoxin
Immunized IV Q3 days for 4 doses 4/10
Challenged IV 12 days after last dose
2.5 mg. of lysostaphin administered over 10 days. A second group received
five doses of 2.5 mg. of lysostaphin on five consecutive days. The first
group was challenged intravenously with both Tris buffer and 2.5 mg. of
lysostaphin 12 days after the last dose. The mice receiving Tris buffer
alone were not affected. While the 10 mice receiving lysostaphin appeared
transiently ill with ruffled hair and shallow respirations, only one mouse
died 30 minutes after the challenge injection.
The second group, having received five daily intravenous doses of
lysostaphin, was challenged with the same dose of lysostaphin 13 days
after the last immunization. All appeared transiently ill but only one
mouse died.
Attempts to demonstrate precipitin antibodies in sera from both lysos-
taphin-immunized groups of mice were unsuccessful (Fig. 10). Further-
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more, in systems containing 50% serum from such mice, no inactivation
of lysostaphin could be shown.
In order to compare the antigenicity of lysostaphin with a foreign pro-
tein that has been used clinically, a group of mice was immunized intra-
venously over a 10-day period with four doses of 0.2 ml. of tetanus anti-
toxin of equine origin. When these mice were challenged intravenously
with 0.2 ml. of tetanus antitoxin 12 days after the last immunization, four
of 10 mice died.
DISCUSSION
The present studies indicate that lysostaphin is superior to penicillin
and oxacillin in the therapy of experimental staphylococcal infections in
mice. This superiority was demonstrated by an increased survival rate
among lysostaphin-treated animals and by greater killing of staphylococci
in vivo. Lysostaphin lowered bacterial titers within well-established renal
abscesses while oxacillin had no demonstrable effect against staphylococcal
populations in such lesions. In mice infected intravenously, a single dose
of lysostaphin produced significantly greater survival rates than did
multiple doses of oxacillin. Thus, lysostaphin appears to be capable of
killing staphylococci within abscess lesions, a situation in which conven-
tional antimicrobials are relatively ineffective.
Staphylococcal L-forms were easily produced by lysostaphin in zitro.
However, they could be recovered from the kidneys of animals infected
intravenously only briefly after treatment with either lysostaphin or
oxacillin and were not demonstrable 24 and 48 hours or 28 days after
treatment. While Kagan has proposed that L-forms may be the cause of
persisting or relapsing staphylococcal disease,' the present studies suggest
that lysostaphin would pose no greater problem in this regard than
penicillin or other antibiotics whose site of action involves cell wall
synthesis.
The major area of concern regarding the possible use of lysostaphin in
humans is its antigenicity. Lysostaphin is a protein with a molecular
weight of about 30,000. It has not been completely purified. The present
studies indicate that precipitin and neutralizing antibodies were evoked in
rabbits, although subsequent intravenous challenge of rabbits with demon-
strable antibody produced no discernible signs of illness.
In contrast, intravenous lysostaphin challenge produced apparent an-
aphylaxis in mice immunized with multiple injections of lysostaphin
emulsified with incomplete Freund's adjuvant. Immunization with lysos-
taphin alone on five successive days or intermittently over 10 days resulted
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in obvious illness, but reduced the death rate to only 10%o. These deleteri-
ous effects in mice were noted only after multiple injections of the enzyme
and when the challenge doses were given 11 and 12 days after the last
immunizing dose.
In contrast to the results observed in rabbits, neutralizing or precipi-
tating antibodies could not be demonstrated in serum obtained from mice
at the time of anaphylaxis. Thus, while lysostaphin proved to be antigenic,
there was a marked species difference in the reaction to this enzyme. Mice
immunized with equine tetanus antitoxin had similar anaphylaxis, and
mortality rates were greater than in mice immunized with lysostaphin on
the same schedule. Thus, despite its antigenicity, lysostaphin like equine
tetanus antitoxin might be administered in a single dose or in a series of
injections over a short period of time without undue risk. The present
animal studies indicate that such a dosage schedule is effective in the
therapy of etablished staphylococcal infection.
While lysostaphin-resistant strains were easily selected in Zitro,j no lyso-
staphin-resistant strains were recovered from infected animals treated
with lysostaphin. Furthermore, the resistant strains recovered in vitro were
unusual staphylococci which appeared in one instance less virulent for mice
and, in both cases, more susceptible to penicillin than the parent strain.
It is possible that lysostaphin-resistant staphylococci may prove to have
reduced disease producing potential, and increased sensitivity to cur-
rently available antimicrobial agents. The striking effectiveness of lysos-
taphin against high titers of staphylococci suggests that use of a single
injection or short course of lysostaphin plus, or followed by, a conventional
anti-staphylococcal antimicrobial may be worth exploring in serious
staphylococcal disease.
SUMMARY
Lysostaphin was superior to the penicillins in the therapy of experi-
mental staphylococcal infections in mice. In contrast to oxacillin, it was
capable of killing staphylococci residing in high titers within abscess
lesions. While staphylococcal L-forms were easily produced by lysostaphin
in vitro, they could be recovered from the kidneys of infected animals
only for a brief time after treatment.
Multiple doses of lysostaphin given over a two-week period evoked
precipitins and neutralizing antibodies in rabbits. Such antibodies could not
be demonstrated in mice but anaphylaxis occurred in mice on challenge.
Single doses of lysostaphin produced no deleterious effects in either animal
species.
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The present studies suggest that lysostaphin, despite its antigenicity,
may deserve evaluation in the therapy of life-threatening staphylococcal
disease. Perhaps the problem of sensitization and lysostaphin-resistant
microorganisms can be avoided by administering only a short course of
lysostaphin, followed by conventional anti-staphylococcal antimicrobial
therapy.
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